Swedish medical device company VibroSense Dynamics AB (Spotlight Stock Market: VSD B), which develops tools for diagnosing nerve damage in the hands and feet, said on Friday it has received regulatory approval in Thailand for VibroSense Meter II.
VibroSense Meter II provides objective, quantitative measurement of vibration perception in the hands and feet and is used to detect peripheral nerve damage not identified by current clinical tools.
The device is now registered as a Class 1 medical device with the Thai Food and Drug Administration, marking a milestone in the company's Southeast Asian expansion and confirming that VibroSense Meter II meets Thailand's safety and performance requirements.
According to VibroSense, Thailand is one of Southeast Asia's largest healthcare markets, with a growing medical technology sector and a strong focus on chronic disease management, including diabetes. Its well-developed public and private hospital system makes the country a strategic market for the company's regional growth plans.
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
SciBase technology selected as primary endpoint in NIH-led skin exposure study
Genezen agrees manufacturing collaboration with Galibra Neuroscience
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
Racura Oncology receives approval for RC220 trial to proceed to higher dose